Frontage Laboratories has made two senior-level appointments to lead its consulting service expansion in regulatory affairs and drug development strategies. Vijay Tammara, Ph.D., was named vice president of Regulatory Affairs and will lead Frontage’s initiative to build a comprehensive regulatory service offering. John (Zhenze) Hu, Ph.D. was named vice president of Pharmaceutical Development Consulting Services and will provide project coordination of multiple drug development disciplines.
Dr. Tammara joins the company from Nuron Biotech, where he led efforts involving regulatory and strategic clinical development support for global development of biologics and vaccines. He also served as director of Regulatory Affairs for Merck Research Laboratories, where he led regulatory activities across a wide range of key therapeutic areas, including cardiovascular, endocrine and gastroenterology.
Dr. Hu brings expertise in development of ophthalmic and dermatologic products, preformulation, formulation, preclinical studies, manufacturing process, project management, regulatory sciences, and technology licensing. Most recently, he served as president of ZhenSight Laboratories, a specialty consulting service for ophthalmic product development. He also worked at Bausch and Lomb, holding several key positions of increasing responsibility.
“I am excited to welcome these two renowned leaders in regulatory affairs and drug development to our company,” said Dr. Song Li, chairman and chief executive officer. “Frontage will continue its strong commitment to exceptional science and service through enhancing internal talent and deepening the range of expertise offered to clients. We look forward to growing our business and serving customers through this strategic service expansion.”